Recent Jobs

  • Regulatory Affairs Associate

    Regulatory Professionals
    Buckinghamshire, Berkshire, >UK
  • Head of Regulatory Affairs, Strategy

    Regulatory Professionals
    UK, Cambridgeshire
  • Regulatory Affairs Director

    Regulatory Professionals
    Europe, Switzerland
  • Head of Regulatory Strategy Consumer Health

    Regulatory Professionals
    UK, Cambridgeshire
Load more listings

Featured Job

Regulatory Affairs Associate

Reference Number: J32422 Regulatory Affairs Associate Location: Berkshire Salary: Up to £40,000 + company benefits Job Reference: J32422 Our client:

Make your job search easier

Create a candidate account to save jobs for later and have the latest roles and career advice emailed to you.

Register for Job Alerts

Create an Account

Complete your online profile and make it easier to apply for roles on the move.

Register your Details

Want to see how you compare to the rest of the industry?

Enter your details to receive a complimentary copy of our salary guide delivered to your door.

Life Science Salary Guide

Regulatory Professionals is one of the fastest growing global integrated regulatory outsourcing providers with a network of 20,000 pharmaceutical professionals globally. Working exclusively within the regulatory functions of Pharmaceutical, Biotechnology, Medical Device, Consumer health / OTC and Diagnostics industries.

Our integrated regulatory affairs recruitment team is there to support partner organisations of all sizes. Ranging for one regulatory consultant, to deliver a specialist project, to outsourcing functional regulatory teams of over 100+, Regulatory Professionals are able to offer global support partnered with expert local knowledge. Our capabilities also offer contract and permanent regulatory staffing services to allow a 360 degree service range for all aspects of regulatory delivery.

Our regulatory recruitment teams approach is tailored to meet the needs of our partners requirements allowing you to shift internal R&D focus to more strategic activities to improve lifecycle performance.

The benefits of Regulatory Professionals integrated teams are measured not just in the savings that could result in multi-mullion dollar cost reductions, but equally in understanding that delays in any part of the regulatory cycle affect the ability to give patients access to transformational products.

Our integrated teams support your product portfolio by giving you flexibility of resource at the peaks and troughs of the product life cycle, while ensuring you maintain control of strategic regulatory departments. This is supported by consistent, measurable and tracked metrics to maximise accountability.

To find out more about each of the regulatory areas we specialise in, take a look at the following regulatory recruitment services:

•    Regulatory Medical Devices
•    Regulatory Clinical
•    Regulatory CMC
•    Regulatory Submissions and Publishing
•    Regulatory Writing
•    Lifecycle Management

Our experienced specialist recruitment consultants are available to speak to you confidentially about our outsourcing regulatory affairs services. To find out more information or to discuss any of our regulatory vacancies, please call our specialist regulatory affairs recruitment team.

+44 (0)118 9522 797

Contact us today to find out how we can progress your career to the next level

Latest News

US FDA gives Fast Track designation to Boehringer Ingelheim’s nintedanib

Boehringer Ingelheim announces the FDA has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD). The FDA’s Fast Track designation enables development of new therapies that treat serious conditions and fulfil an unmet medical need in an effort to get treatments to those in need sooner.

Continue Reading


MSD receive FDA fast track review for Keytuda to treat cervical cancer

US regulators will conduct a priority review of MSD’s Keytruda to treat patients with advanced cervical cancer. The company is seeking approval for the drug’s use in patients with cervical cancer who experience disease progression during or post chemotherapy. The FDA’s decision marks the first filing acceptance and priority review issued for an anti-PD-1 therapy

Continue Reading